Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Auris Medical (NQ: EARS )

3.140 USD -0.010 (-0.32%)
Official Closing Price Updated: 6:30 PM EST, Jan 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Auris Medical

< Previous 1 2 Next >
Auris Medical Provides Business Update
From GlobeNewswire News Releases
Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference
From GlobeNewswire News Releases
Auris Medical Holding Ltd. Prices $8,000,000 Common Shares Offering Priced At-the-Market
From GlobeNewswire News Releases
Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection
From GlobeNewswire News Releases
Auris Medical Launches Website for AM-301-focused Subsidiary, Altamira Medica
From GlobeNewswire News Releases
Auris Medical Announces Initiation of Part B of TRAVERS Phase 2 Study with AM-125 in Vertigo
From GlobeNewswire News Releases
Auris Medical Provides Business Update and Reports First Half 2020 Financial Results
From GlobeNewswire News Releases
Auris Medical to Report First Half 2020 Financial Results and Provide Business Update on Thursday, September 17, 2020
From GlobeNewswire News Releases
Auris Medical Launches Development of Drug-Free Nasal Spray for Protection against Airborne Pathogens and Allergens
From GlobeNewswire News Releases
Auris Medical Announces Positive Interim Data from TRAVERS Phase 2 Study with AM-125 in Vertigo
From GlobeNewswire News Releases
Auris Medical Regains Listing Compliance with NASDAQ Minimum Bid Requirement
From GlobeNewswire News Releases
Auris Medical Announces Completion of Enrollment into First Part of TRAVERS Phase 2 Study with AM-125 in Vertigo
From GlobeNewswire News Releases
Auris Medical Announces Positive Top-Line Data from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain and Provides Update on TRAVERS Phase 2 Study
From GlobeNewswire News Releases
Auris Medical Provides Business Update and Reports Second Half and Full Year 2019 Financial Results
From GlobeNewswire News Releases
Auris Medical Provides Update on Intranasal Betahistine Development Program
From GlobeNewswire News Releases
Auris Medical Provides Update on Ongoing Clinical Trials with Intranasal Betahistine
From GlobeNewswire News Releases
Auris Medical Highlights Publication of Study Results Demonstrating Betahistine’s Antiepileptogenic and Anticonvulsant Activity in Murine Model
From GlobeNewswire News Releases
Auris Medical Announces Notice of Allowance for European Patent Application
From GlobeNewswire News Releases
Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss
From GlobeNewswire News Releases
Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain
From GlobeNewswire News Releases
Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program
From GlobeNewswire News Releases
Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine
Received Notice of Allowance from United States Patent and Trademark Office -- Received “Intention to Grant” notice from European Patent Office 
From GlobeNewswire News Releases
Auris Medical Announces Appointment of New Chief Financial Officer
From GlobeNewswire News Releases
Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs
From GlobeNewswire News Releases
Auris Medical Provides Business Update and Reports First Half 2019 Financial Results
From GlobeNewswire News Releases
Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,... 
From GlobeNewswire News Releases
Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,... 
From GlobeNewswire News Releases
Auris Medical Holding Ltd Provides Corporate Update
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,... 
From GlobeNewswire News Releases
Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders... 
From GlobeNewswire News Releases
Auris Medical Announces Closing of Public Offering of Common Shares
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,... 
From GlobeNewswire News Releases
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.